DLinDMA is widely used in the development of lipid nanoparticles for drug delivery systems, particularly in the field of gene therapy. Its primary application is in the formulation of lipid-based carriers that encapsulate nucleic acids, such as siRNA or mRNA, to facilitate their efficient delivery into target cells. This compound is a key component in creating stable and biocompatible nanoparticles that protect genetic material from degradation and enhance cellular uptake. Its use has been instrumental in advancing therapeutic approaches for treating genetic disorders, cancers, and infectious diseases by enabling precise and effective delivery of therapeutic genes. Additionally, DLinDMA-based formulations are being explored in vaccine development, particularly for mRNA vaccines, due to their ability to induce strong immune responses. Its versatility and effectiveness make it a critical material in modern biotechnology and pharmaceutical research.